Specify a stock or a cryptocurrency in the search bar to get a summary
Novartis AG ADR
NOVNNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Address: Lichtstrasse 35, Basel, Switzerland, 4056
Analytics
WallStreet Target Price
115.96 USDP/E ratio
23.9243Dividend Yield
3.23 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NOVN
Dividend Analytics NOVN
Dividend growth over 5 years
30 %Continuous growth
2 yearsPayout Ratio 5 years average
80 %Dividend History NOVN
Stock Valuation NOVN
Financials NOVN
Results | 2019 | Dynamics |